Press Releases

2017.04.28 Corporate PDF (91KB)
Daiichi Sankyo Announces the Introduction of a Restricted Share-Based Remuneration Plan
2017.04.28 Corporate PDF (165KB)
Daiichi Sankyo Revises Fiscal 2016 Consolidated Forecasts and Announces Fiscal 2017 Consolidated Forecasts
2017.04.28 Corporate PDF (91KB)
Daiichi Sankyo Announces Impairment Loss Related to Kitasato Daiichi Sankyo Vaccine
2017.04.27 Corporate PDF (42KB)
Daiichi Sankyo Announces 15 Billion Yen Manufacturing Investment to Support Acceleration of Antibody Drug Conjugate Portfolio
2017.04.24 R&D PDF (89KB)
Daiichi Sankyo Announces Designation of Duchenne Muscular Dystrophy Treatment DS-5141 under “SAKIGAKE Designation System”
2017.04.04 Corporate PDF (48KB)
Daiichi Sankyo, Inc. Announces Sale of Pharmaceutical Packaging Plant in Bethlehem, PA
2017.03.31 R&D PDF (99KB)
Daiichi Sankyo Initiates ELIMINATE-AF Study Investigating Once-Daily Lixiana® (edoxaban) in Patients Undergoing Catheter Ablation of Non-valvular Atrial Fibrillation
2017.03.30 Local (JPN) PDF (70KB)
Daiichi Sankyo Announces Manufacture and Sales Approval in Japan of Narurapid® Tablets and Narusus® Tablets for Cancer Pain Treatment
2017.03.30 Products PDF (15KB)
Daiichi Sankyo Submits Application for Additional Indication and Dosage for Ovisot® Intracoronary Injection 0.1g in Diagnosis of Vasospastic Angina
2017.03.30 Corporate PDF (33KB)
Daiichi Sankyo Announces Collaborative Research on Drugs for Neglected Tropical Diseases
2017.03.29 Local (JPN) PDF (62KB)
Mitsubishi Tanabe Pharma and Daiichi Sankyo to Expand Strategic Alliance in the Diabetes Field
2017.03.23 R&D PDF (92KB)
Daiichi Sankyo to Facilitate New Drug Discovery in 2017 through Collaborative Research and Grants
2017.03.16 Corporate PDF (55KB)
The National Institutes of Biomedical Innovation, Health and Nutrition, Daiichi Sankyo,and Mitsubishi UFJ Capital Announce Open Innovation Research on New Cancer Immunotherapy
2017.03.13 R&D PDF (35KB)
Daiichi Sankyo Announces Large-scale Registry of Venous Thromboembolism (VTE) in Cancer Patients
2017.03.13 Corporate PDF (41KB)
Daiichi Sankyo Enters Agreement with Heptares Therapeutics to Discover and Develop Novel, Small-Molecules for the Treatment of Pain
2017.03.08 Local (JPN) PDF (43KB)
Daiichi Sankyo Announces New Oxycodone Extended Release Tablets "Daiichi Sankyo" for Sustained Cancer Pain Treatment
2017.03.07 R&D PDF (98KB)
Daiichi Sankyo Initiates ENTRUST-AF PCI Study Investigating Once-Daily Lixiana® (edoxaban) in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention with Stenting
2017.03.03 CSR PDF (73KB)
Winner of 2016 Manpei Suzuki International Prize for Diabetes Research Announced
2017.03.01 R&D PDF (149KB)
Commencement of Phase 1 Trial for the Mutant IDH1 Inhibitor (DS-1001) Targeting Malignant Brain Tumors
2017.02.24 Corporate PDF (85KB)
Daiichi Sankyo Appoints New Group Corporate Officers
2017.02.24 Corporate PDF (97KB)
Daiichi Sankyo Announces Organizational Restructuring Effective as of April 1, 2017
2017.02.22 Corporate PDF (15KB)
Daiichi Sankyo Joins “IkuBoss Alliance”
2017.02.20 R&D PDF (64KB)
Daiichi Sankyo and ArQule Announce the Completion of the METIV-HCC Phase 3 Study of Tivantinib in Second-Line Treatment of MET-Overexpressing Hepatocellular Carcinoma
2017.02.15 Local (JPN) PDF (18KB)
Daiichi Sankyo Strengthens Authorized Generic Business through Daiichi Sankyo Espha
2017.02.10 Corporate PDF (75KB)
Daiichi Sankyo Announces Further Reorganization of its Research & Development Structure
2017.02.06 R&D PDF (55KB)
Charleston Laboratories, Inc. and Daiichi Sankyo, Inc. Receive Complete Response Letter from FDA for New Drug Application for CL-108 (hydrocodone, acetaminophen, promethazine) Tablets for Oral Use
2017.02.02 CSR PDF (18KB)
Daiichi Sankyo Announces Continuation of Mobile Healthcare Field Clinic Service Aimed at Improving Healthcare Access in Tanzania
2017.01.31 Corporate PDF (29KB)
Daiichi Sankyo Announces New Chairman and President
2017.01.19 R&D PDF (44KB)
Daiichi Sankyo Initiates Phase 1/2 Study of Novel Antibody Drug Conjugate U3-1402 in Patients with HER3-Positive Metastatic or Unresectable Breast Cancer
2017.01.18 CSR PDF (13KB)
Daiichi Sankyo Announces Participation in the Global Initiative, Access Accelerated
2017.01.10 Corporate PDF (21KB)
Daiichi Sankyo Announces Reorganization of Research & Development System
2017.01.10 Corporate PDF (17KB)
Daiichi Sankyo Establishes Strategic Partnership for Cellular Therapy Pipeline with Kite Pharma

In order to view the PDF files, you need to have the latest version of Adobe Reader installed.